Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have earned a consensus rating of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $19.00.

Several research analysts have weighed in on the stock. Wedbush upped their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, October 17th. Jefferies Financial Group upgraded Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. HC Wainwright boosted their target price on Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Thursday, October 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 17th.

Artiva Biotherapeutics Trading Down 27.8%

Shares of ARTV stock opened at $4.55 on Wednesday. The company has a market capitalization of $111.70 million, a price-to-earnings ratio of -1.76 and a beta of 3.10. Artiva Biotherapeutics has a 1-year low of $1.47 and a 1-year high of $11.55. The stock’s fifty day simple moving average is $3.74 and its 200-day simple moving average is $2.93.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. On average, sell-side analysts predict that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Insider Transactions at Artiva Biotherapeutics

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $6.00, for a total value of $153,000.00. Following the completion of the sale, the chief executive officer directly owned 356,721 shares in the company, valued at $2,140,326. The trade was a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 35,062 shares of company stock valued at $193,670 in the last ninety days. 21.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its holdings in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Artiva Biotherapeutics by 26.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after purchasing an additional 11,355 shares during the last quarter. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics during the third quarter worth approximately $41,000. Ground Swell Capital LLC acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth $38,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Artiva Biotherapeutics during the second quarter valued at about $48,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.